Your Article Summary
See Latest ArticlesThe Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III
Value in Health, 06/26/09
Stevenson M et al. - Bosentan is likely to be a more cost-effective first-line therapy for patients with PAH FC III in the UK than no active intervention.
Related Articles
Economic evaluation of arthritis self management in primary care
British Medical Journal, 10/08/09
Relevance Score: 87%
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis
Internal and Emergency Medicine, 11/10/09
Relevance Score: 84%
Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis
British Medical Journal, 10/08/09
Relevance Score: 84%
Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09
Relevance Score: 84%
Fine-needle aspiration of primary osseous lesions: A cost effectiveness study
Diagnostic Cytopathology, 10/06/09
Relevance Score: 84%
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Presidential order targets improper federal payments
American Hospital Association News, 12/15/09
Community safety net
American Hospital Association News, 12/14/09
Cash flow squeeze: 2012 IRS rule will withhold some Medicare pay
American Medical News , 12/11/09